Camargo

NOVEMBER 11, 2020

When the FDA requires a product’s labeling to include a boxed warning (also called a “black box warning” because the text is surrounded by black border), the potential market value of the drug often drops severely. Presumably, Antares’ long-established 90-person urology sales force can achieve pull-thru of this drug product.

Development 242

Development Bioequivalency Generic Drugs Production 242

FDA Law Blog

FEBRUARY 26, 2024

Relevant here, FDA interpreted in Guidance that a proposed injectable biosimilar must “demonstrate that its product has the same strength as the reference product by demonstrating that both products have the same total content of drug substance (in mass or units of activity) and the same concentration of drug substance.”

Production 59

Production Bioequivalency Drugs Containment 59

pharmaphorum

OCTOBER 21, 2020

Zosano Pharma has been hit by an FDA rejection of its marketing application for migraine drug Qtrypta, asking for new bioequivalence data. Qtrypta is Zosano’s lead product candidate, but the company is also working on a follow-up in phase 2/3 for cluster headache.

Bioequivalency 52

Bioequivalency Production Drugs Manufacturing 52

Drug Discovery World

AUGUST 22, 2023

In September 2021, the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) announced the initiation of a pilot programme 1 to provide parallel scientific advice to pharma companies applying for marketing authorisation for generic versions of hybrid products and complex generic drug products.

Production 52

Production Bioequivalency In-Vivo In-Vitro 52

Camargo

JULY 8, 2021

At Camargo, we have worked with hundreds of investigators who have found new targets for established drugs. It is exciting to find new uses of drugs with known safety because these drugs can reach new groups of patients in a relatively short timeframe.

Development 130

Development Bioequivalency Gene Expression Drugs 130

FDA Law Blog

JULY 6, 2021

Koblitz — FDA has long taken the position that a Complete Response Letter (“CRL”)—a letter sent when FDA has determined that it “cannot approve” a New Drug Application (“NDA”) or an Abbreviated New Drug Application (“ANDA”) “in its present form”—is not a final agency action and thereby not subject to challenge in Court. 314.110(c).

Bioequivalency 52

Bioequivalency Bioavailability Regulation Drugs 52

pharmaphorum

JANUARY 18, 2023

NewAmsterdam Pharma’s bold play to resurrect an all-but defunct cholesterol-lowering drug class has been rewarded with a positive phase 2 trial of its oral CETP inhibitor obicetrapib. Ezetimibe was originally developed by Merck & Co as Zetia and is now available in generic form.

Bioequivalency 58

Bioequivalency Trials Licensing Licensing 58

Pharmacy Checkers

FEBRUARY 14, 2020

Years ago, they took on the Food and Drug Administration in regards to Budeprion XL distributed by Teva Pharmaceuticals, the supposed generic equivalent to the popular antidepressant, Wellbutrin XL. Finally, I put it together that this was related to the drug because when I wouldn’t take it I would begin to feel better.

Branding 62

Branding FDA Approval Pharmacy Bioequivalency 62

pharmaphorum

JANUARY 17, 2022

The man who sent the price of lifesaving drug Daraprim (pyrimethamine) rocketing from $13.50 Until recently, Daraprim was the only drug available to treat the disease and has been the gold standard treatment for toxoplasmosis for decades. a tablet to $750 overnight has been ordered to repay $64.6m (£47m).

Bioequivalency 45

Bioequivalency Generic Drugs Contamination Drugs 45

The Pharma Data

DECEMBER 28, 2020

Food and Drug Administration (“FDA”) has approved its Abbreviated New Drug Application (“ANDA”) for Glucagon for Injection Emergency Kit, 1 mg. This further highlights Amphastar’s considerable abilities to bring complex generic drugs to the market, and more specifically, our strong peptide capabilities.”

Bioequivalency 52

Bioequivalency Production Sales Marketing 52

Camargo

DECEMBER 13, 2021

Both the FDA’s Center for Drug Evaluation and Research (CDER) and its Center for Biologics Evaluation and Research (CBER) have regulatory responsibility for therapeutic biological products, which are subject to both the Federal Food, Drug and Cosmetic (FD & C) Act and the Public Health Service (PHS) Act.

Development 161

Development Production Immune Response Licensing 161

Drug Discovery World

JULY 25, 2023

Upcoming milestones for the CYB003 program Completion of CYB003 dosing in MDD cohorts expected in Q3 2023 Topline efficacy data readout from CYB003 Phase II clinical trial expected in Q3/Q4 2023 US Food and Drug Administration (FDA) submission of CYB003 Phase I/IIa data for pivotal studies expected following topline efficacy data readout About (..)

Trials 52

Trials Bioequivalency Clinical Trials Clinical Trials 52

Camargo

FEBRUARY 10, 2021

Drug development is an extremely cumbersome process, requiring the testing of an agent from in vitro studies to in vivo studies to in silico modeling. Given that it can take up to 20 years for a final product to be approved, it is unsurprising that drug attrition rates are very high.

Production 133

Production Bioavailability In-Vivo Bioequivalency 133

Pharmaceutical Technology

JULY 25, 2022

Specialty generics is a term used to refer to generic versions of drugs that are often expensive, complex, or “high touch”—requiring significant involvement of service to manage. Specialty drugs are most used to treat different cancers, rheumatoid arthritis, and multiple sclerosis. The only way forward for generics producers.

Drugs 298

Drugs Manufacturing Production Pharmacy 298

The Pharma Data

FEBRUARY 1, 2021

Food and Drug Administration (FDA) has approved a new intramuscular (IM) injection route of administration for Plegridy ® ( peginterferon beta-1a ) for the treatment of relapsing forms of multiple sclerosis (MS). CAMBRIDGE, Mass., 01, 2021 (GLOBE NEWSWIRE) — Biogen Inc. Nasdaq: BIIB) today announced that the U.S. percent vs. 32.1

FDA Approval 40

FDA Approval Bioequivalency Clinical Trials Clinical Trials 40

The Pharma Data

NOVEMBER 17, 2021

VUMERITY is a coming- generation fumarate that offers the convenience of an oral drug with the established efficacity and well- characterized safety of TECFIDERA ® (dimethyl fumarate). Encyclopedically, an estimated2.8 million people live with MS, with further than 1 million people in Europe living with the complaint. “

Marketing 52

Marketing Bioequivalency Clinical Trials Clinical Trials 52

Delveinsight

FEBRUARY 5, 2021

Fortunately, there exists FDA-approved therapies and drugs that double the success rates of quitting. Smoking Cessation: What are the drugs available in the market? The USFDA’s Center for Drug Evaluation and Research regulates and ensures the safety and effectiveness of these products. However, it is possible.

Marketing 52

Marketing FDA Approval Branding Production 52

XTalks

FEBRUARY 8, 2021

In order to fact-check some of these misconceptions, the US Food and Drug Administration (FDA) recently hosted a webinar on biosimilar and interchangeable biological products to help healthcare professionals understand more about these treatment options. Biosimilars are the “generic” drugs of the biopharma world. What is a Biosimilar?

Production 78

Production Insulin Branding Generic Drugs 78

The Pharma Data

SEPTEMBER 26, 2021

The positive CHMP opinion was supported data from pharmacokinetic bridging studies comparing VUMERITY and TECFIDERA® (dimethyl fumarate) to determine bioequivalent exposure of monomethyl fumarate, the active metabolite, and relied partially on the well-established long-term safety and efficacy profile of TECFIDERA. for TECFIDERA.

Clinical Trials 40

Clinical Trials Clinical Trials Bioequivalency Medicine 40

The Pharma Data

APRIL 11, 2023

Dose proportionality and bioequivalence studies demonstrate once-daily AUSTEDO XR is therapeutically equivalent to twice-daily AUSTEDO ® (deutetrabenazine) tablets The U.S. Bioequivalence and relative bioavailability were established between the once-daily and twice-daily tablet formulations, with no new safety findings emerging.

Bioequivalency 40

Bioequivalency FDA Approval Bioavailability Medicine 40

FDA Law Blog

JULY 24, 2022

Koblitz — The Orange Book’s Therapeutic Equivalence Codes (TE Codes) play a critical role in our drug distribution and payment system. The Guidance explains that only certain drug products are evaluated for therapeutic equivalence. FDA goes through each of the relevant terms and the therapeutic equivalence requirements.

Bioequivalency 40

Bioequivalency Production Packaging Packaging 40

Druggist

MARCH 25, 2021

Do generic, and branded drugs produce exactly the same effect? . In terms of prescribing, both contraceptives are regarded as the same drug. . As with other drugs, once a patent expires, other manufactures start to produce generic or new brands of the same pill (desogestrel). Can I still request a doctor to prescribe Cerazette?

Branding 98

Branding Bioequivalency Pharmacy Generic Drugs 98

FDA Law Blog

JANUARY 23, 2023

Livornese — Last month, Congress took a big step towards improving clinical trial diversity by requiring sponsors of most drug and device clinical studies to submit a diversity action plan when they submit key trial documents to the Food and Drug Administration (FDA).

Trials 59

Trials Clinical Trials Clinical Trials Drugs 59

The Pharma Data

AUGUST 5, 2020

The US Food and Drug Administration and European Medicines Agency are currently reviewing ofatumumab for the treatment of relapsing forms of multiple sclerosis (RMS) in adults . Onset of B-cell depletion with subcutaneous administration of ofatumumab in relapsing multiple sclerosis: results from the APLIOS bioequivalence study.

Trials 52

Trials Medicine Production Containment 52

The Pharma Data

DECEMBER 17, 2020

In addition, TLC is preparing for scale-up production of TLC590, as for complex lipid products, the manufacturing process and batch size used in pivotal clinical trials and New Drug Application submission must be the same as future commercial batches.

Clinical Trials 40

Clinical Trials Clinical Trials Trials Containment 40

The Pharma Data

DECEMBER 27, 2020

The drug, Yeliva (opaganib) is a first-in-class, oral spingosine kinase-2 (SK2) selective inhibitor with triple-action effect on the pathophysiological processes linked to COVID-19. The drug is a humanized IgG4 monoclonal antibody that blocks CCR5 and is being developed for COVID-19, HIV and metastatic triple-negative breast cancer.

Trials 52

Trials Antibody Gene Therapy Clinical Trials 52

The Pharma Data

AUGUST 9, 2021

Food and Drug Administration (FDA) approved SKYRIZI 150 mg in April based on data from three clinical trials showing the single-dose SKYRIZI 150 mg injection was bioequivalent, working the same as two injections of SKYRIZI 75 mg per dose with a consistent efficacy and safety profile. ” The U.S.

Bioequivalency 52

Bioequivalency Vaccination Vaccine Medicine 52

Pharmaceutical Technology

FEBRUARY 23, 2023

Biopharmaceutics is a scientific discipline that examines the interrelationship of the physicochemical properties of the drug, the dosage form in which the drug is given, and the route of administration on the rate and extent of systemic drug absorption ( Applied Biopharmaceutics and Pharmacokinetics, Shargel, Wu-Pong and Yu, 5th Edition ).

Development 246

Development Drugs Bioavailability In-Vivo 246

The Pharma Data

MAY 3, 2021

Drug distributors face off against West Virginia in billion-dollar opioid trial ( Reuters ) ( Law360 ). Amgen’s KRAS cancer drug had a bad week, but worry about pricing, not safety ( STAT ). Mental health/psychedelic drugs: mushrooming investor interest fuels research ( FT ). Medtech.

Gene Therapy 52

Gene Therapy Vaccination Vaccine Bioequivalency 52

Pharmaceutical Technology

JANUARY 6, 2023

In vitro release testing to demonstrate bioequivalence. Even the smallest details can have a big impact on the end result, especially when it comes to the sensory characteristics and the bioequivalence of a topical product. Fixed dose combination drugs: Case study. To find out more, download the whitepaper below.

Production 130

Production Manufacturing Development Bioequivalency 130